9EN Stock Chart & Stats
€29.70
€0.30(1.02%)
At close: 4:00 PM EDT
€29.70
€0.30(1.02%)
Day’s Range― - ―
52-Week Range€16.30 - €31.65
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
€2.05B
Enterprise Value€1.56K
Total Cash (Recent Filing)€246.96M
Total Debt (Recent Filing)€738.89K
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 19, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding69,863,686
10 Day Avg. Volume0
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€44.39Price Target Upside49.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Lead Program Advancement (deucrictibant)Advancing a lead oral HAE candidate into pivotal Phase 3 and an imminent NDA filing materially de-risks the development timeline versus earlier-stage peers. Late-stage status supports clearer regulatory and commercial planning, increases the probability of eventual product revenues, and attracts partnership or payer engagement over the medium term.
Extended Cash Runway Into 2028 After FinancingA multi-year cash runway provides durable financing visibility to complete pivotal trials, regulatory submissions, and initial commercial build activities. This reduces near-term funding urgency, allowing management to execute clinical milestones and early commercialization investments without immediate refinancing pressure.
Very Low Financial LeverageExtremely low debt gives structural financial flexibility: limited interest obligations and lower default risk. This conservatively levered capital structure improves the company's ability to prioritize R&D and commercial investment, and to access additional capital if needed without immediate solvency pressure.
Bears Say
Pre-revenue Status With Materially Widening LossesSustained pre-revenue operations and rapidly widening losses reflect heavy investment without offsetting sales, creating persistent negative operating leverage. Continued cash burn increases funding need risk and means long-term value realization depends heavily on successful clinical and regulatory outcomes rather than current cash generation.
Dependence On Equity Financing And Dilution RiskFrequent reliance on public equity issuances to fund operations signals limited internal cash generation and exposes shareholders to dilution risk if additional raises are required. Over the medium term, recurring reliance on capital markets can compress per-share economics and complicate long-term return profiles for existing investors.
Declining Equity Base And Sharply Negative ROEMaterial erosion of shareholder equity and very negative returns on capital indicate capital has been consumed by losses rather than value-creating investments. This reduces the balance-sheet buffer for setbacks, raises the probability of future financing need, and highlights weak historical capital efficiency that may persist until commercialization.
Pharvaris News
9EN FAQ
What was Pharvaris N.V.’s price range in the past 12 months?
Pharvaris N.V. lowest stock price was €16.30 and its highest was €31.65 in the past 12 months.
What is Pharvaris N.V.’s market cap?
Pharvaris N.V.’s market cap is €2.05B.
When is Pharvaris N.V.’s upcoming earnings report date?
Pharvaris N.V.’s upcoming earnings report date is Aug 19, 2026 which is in 17 days.
How were Pharvaris N.V.’s earnings last quarter?
Pharvaris N.V. released its earnings results on May 12, 2026. The company reported €0.59 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pharvaris N.V. overvalued?
According to Wall Street analysts Pharvaris N.V.’s price is currently Undervalued.
Does Pharvaris N.V. pay dividends?
Pharvaris N.V. does not currently pay dividends.
What is Pharvaris N.V.’s EPS estimate?
Pharvaris N.V.’s EPS estimate is -0.65.
How many shares outstanding does Pharvaris N.V. have?
Pharvaris N.V. has 69,863,686 shares outstanding.
What happened to Pharvaris N.V.’s price movement after its last earnings report?
Pharvaris N.V. reported an EPS of €0.59 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.238%.
Which hedge fund is a major shareholder of Pharvaris N.V.?
Currently, no hedge funds are holding shares in DE:9EN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€44.39 (49.47% Upside)
€44.39 (49.47% Upside)
Blogger Sentiment
Bullish
DE:9EN Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.71%
Trailing 12-Months
Company Description
Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
9EN Stock 12 Month Forecast
Average Price Target
€44.39
▲(49.47% Upside)